| CYPHERPUNK TECHNOLOGIES |
| USA |
| Gesundheit |
| US52187K2006 / A3EMJP |
| 5MC (Frankfurt) / CYPH (NASDAQ) |
| FRA:5MC, ETR:5MC, 5MC:GR, NASDAQ:CYPH |
| - |
| https://www.leaptx.com/ |
|
Cypherpunk Technologies Inc. is a biopharmaceutical company focused on developing novel antibody therapies for cancer treatment, with a strategic emphasis on biomarker-targeted approaches. The company..
>Volltext.. |
| 28.78 Mio. EUR |
| 20.49 Mio. EUR |
| - |
| -41.66 Mio. EUR |
| -44.51 Mio. EUR |
| -1.08 EUR |
| 0.03 Mio. EUR |
| 8.48 Mio. EUR |
| -46.24 Mio. EUR |
| 1.11 |
| - |
| 25.35% |
| - |
| - |
| - |
| - |
| CYPHERPUNK, LEAP THERAPEUTICS |
| 17.03.26 |
|